Bayer Detailed Consensus >> Segments
Last Update: 2020-09-08

Please note:

All 2019 figures were re-based to reflect the change in cost allocations from enabling functions to the divisions effective Jan. 1, 2020.


KPI[EUR m]Q3 2019FY 2019Q3 2020 EFY 2020 EFY 2021 EFY 2022 EFY 2023 EFY 2024 E
Pharmaceuticals, SalesNumber of Estimates101314131212
Pharmaceuticals, SalesHighest4,39717,87518,71519,59321,03520,275
Pharmaceuticals, SalesAverage4,50417,9624,27417,46218,12718,74218,72317,890
Pharmaceuticals, SalesMedian4,27317,39218,11518,79918,53717,639
Pharmaceuticals, SalesLowest4,14117,23317,69317,94117,33016,373
XareltoNumber of Estimates91111111111
XareltoHighest1,1494,6425,2115,7186,2615,689
XareltoAverage1,0344,1261,0964,5044,8995,1884,9643,880
XareltoMedian1,1024,4974,9175,2065,2363,800
XareltoLowest1,0334,4054,6574,6553,7852,611
EyleaNumber of Estimates91111111111
EyleaHighest6672,5422,7532,7532,7532,816
EyleaAverage6402,4946282,4632,5672,5822,5572,501
EyleaMedian6292,4442,5632,6072,5572,504
EyleaLowest5912,4082,3952,3472,2302,118
Mirena product familyNumber of Estimates91111111111
Mirena product familyHighest3091,1401,2701,3231,3561,390
Mirena product familyAverage3021,2232621,0641,1461,1621,1791,194
Mirena product familyMedian2611,0591,1491,1861,2141,219
Mirena product familyLowest2089421,057904814733
Kogenate (incl. Kovaltry, Jivi)Number of Estimates91111111111
Kogenate (incl. Kovaltry, Jivi)Highest231918900918936955
Kogenate (incl. Kovaltry, Jivi)Average226882215866829797764734
Kogenate (incl. Kovaltry, Jivi)Median217878849811798748
Kogenate (incl. Kovaltry, Jivi)Lowest197751699661597535
NexavarNumber of Estimates91111111111
NexavarHighest167675634531446419
NexavarAverage181706143598418324246214
NexavarMedian159627463308240212
NexavarLowest97490121977762
Pharmaceuticals, EBITDA before special itemsNumber of Estimates101313131212
Pharmaceuticals, EBITDA before special itemsHighest1,5386,0966,6217,0507,6158,110
Pharmaceuticals, EBITDA before special itemsAverage1,5275,8611,4776,0246,3106,6166,6536,100
Pharmaceuticals, EBITDA before special itemsMedian1,4936,0346,3866,6236,6006,191
Pharmaceuticals, EBITDA before special itemsLowest1,3835,8496,0606,1555,7864,526
Consumer Health, SalesNumber of Estimates101314131212
Consumer Health, SalesHighest1,3585,5045,5545,6775,8035,975
Consumer Health, SalesAverage1,2885,4621,2495,2045,2755,4195,5775,725
Consumer Health, SalesMedian1,2395,1905,2745,4445,6045,758
Consumer Health, SalesLowest1,1945,0495,0555,1945,2875,383
Consumer Health, EBITDA before special itemsNumber of Estimates101313131212
Consumer Health, EBITDA before special itemsHighest2991,2141,3331,4191,5091,601
Consumer Health, EBITDA before special itemsAverage2561,1422841,1591,2221,2941,3411,386
Consumer Health, EBITDA before special itemsMedian2851,1591,2361,3161,3651,404
Consumer Health, EBITDA before special itemsLowest2691,0701,0821,1201,1261,160
CropScience, SalesNumber of Estimates101314131212
CropScience, SalesHighest4,06320,37621,10322,21423,24024,645
CropScience, SalesAverage3,94819,8323,67119,59219,86120,50821,07821,767
CropScience, SalesMedian3,65219,51019,84820,34820,71521,292
CropScience, SalesLowest3,40118,92318,85519,52520,22120,651
CropScience, EBITDA before special itemsNumber of Estimates101313131212
CropScience, EBITDA before special itemsHighest6325,1255,7226,4316,7947,261
CropScience, EBITDA before special itemsAverage5274,7144554,9585,3695,9046,0906,323
CropScience, EBITDA before special itemsMedian4294,9505,3555,8916,1106,386
CropScience, EBITDA before special itemsLowest3304,8255,0935,4815,4425,575
Reconciliation, SalesNumber of Estimates101314131212
Reconciliation, SalesHighest92295301307313319
Reconciliation, SalesAverage9028975272273272273274
Reconciliation, SalesMedian77286286280285285
Reconciliation, SalesLowest37200190181171163
Reconciliation, EBITDA before special itemsNumber of Estimates101313131212
Reconciliation, EBITDA before special itemsHighest-38-22366336336336
Reconciliation, EBITDA before special itemsAverage-19-245-84-349-303-276-277-279
Reconciliation, EBITDA before special itemsMedian-85-350-350-300-325-325
Reconciliation, EBITDA before special itemsLowest-123-420-420-428-437-457
Disclaimer

This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.